Evidence map›Paper›PMID 26430739›Full record

ArticlePloS one2015

MicroRNA Expression in Myocardial Tissue and Plasma of Patients with End-Stage Heart Failure during LVAD Support: Comparison of Continuous and Pulsatile Devices.

Sjoukje I Lok, Nicolaas de Jonge, Joyce van Kuik, Ankie J P van Geffen, Manon M H Huibers, Petra van der Weide, Erica Siera, Bjorn Winkens, Pieter A Doevendans, Roel A de Weger and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sjoukje I LokDepartment of Cardiology, University Medical Center, Utrecht, the Netherlands; Department of Pathology, University Medical Center, Utrecht, the Netherlands.
Nicolaas de JongeDepartment of Cardiology, University Medical Center, Utrecht, the Netherlands.
Joyce van KuikDepartment of Pathology, University Medical Center, Utrecht, the Netherlands.
Ankie J P van GeffenDepartment of Pathology, University Medical Center, Utrecht, the Netherlands.
Manon M H HuibersDepartment of Pathology, University Medical Center, Utrecht, the Netherlands.
Petra van der WeideDepartment of Pathology, University Medical Center, Utrecht, the Netherlands.
Erica SieraDepartment of Pathology, University Medical Center, Utrecht, the Netherlands.
Bjorn WinkensDepartment of Methodology and Statistics, Maastricht University, Maastricht, the Netherlands.
Pieter A DoevendansDepartment of Cardiology, University Medical Center, Utrecht, the Netherlands.
Roel A de WegerDepartment of Pathology, University Medical Center, Utrecht, the Netherlands.
Paula A da Costa MartinsDepartment of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimPulsatile flow left ventricular assist devices (pf-LVADs) are being replaced by continuous flow LVADs (cf-LVADs) in patients with end-stage heart failure (HF). MicroRNAs (miRs) play an important role in the onset and progression of HF. Our aim was to analyze cardiac miR expression patterns associated with each type of device, to analyze differences in the regulation of the induced cardiac changes. METHODS AND

resultsTwenty-six miRs were selected (based on micro-array data and literature studies) and validated in myocardial tissue before and after pf- (n = 17) and cf-LVAD (n = 17) support. Of these, 5 miRs displayed a similar expression pattern among the devices (miR-129*, miR-146a, miR-155, miR-221, miR-222), whereas others only changed significantly during pf-LVAD (miR-let-7i, miR-21, miR-378, miR-378*) or cf-LVAD support (miR-137). In addition, 4 miRs were investigated in plasma of cf-LVAD supported patients (n = 18) and healthy controls (n = 10). Circulating miR-21 decreased at 1, 3, and 6 months after LVAD implantation. MiR-146a, miR-221 and miR-222 showed a fluctuating time pattern post-LVAD.

conclusionOur data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels.

Indexed as

Heart-Assist DevicesAdultFemaleHeart FailureHumansMaleMicroRNAsMiddle AgedMyocardiumMicroRNAs

Identifiers

PMID26430739
PMCPMC4592005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.